You just read:

New Follow-Up Data for IMBRUVICA® (ibrutinib) Presented at ASH Show Longer Term Efficacy in Patients with Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma

News provided by

Janssen-Cilag International NV

09 Dec, 2014, 08:00 GMT